Form 4 for DNTH Dianthus Therapeutics, Inc. /DE/
Accepted 2026-08-19 18:02:39 ET · period of report 2026-08-19 · accession 0001688199-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-19 18:02 | 2026-08-19 | DNTH | Read Simon | Dir | M - OptEx | $18.36 | +2,778 | 2,778 | New | +$51.0K |
| DT | 2026-08-19 18:02 | 2026-08-19 | DNTH | Read Simon | Dir | S - Sale+OE | $117.55 | -2,778 | 0 | -100% | -$326.6K |
| DT | 2026-08-19 18:02 | 2026-08-19 | DNTH | Read Simon | Dir | M - OptEx | $0.00 | -2,778 | 19.4K | -13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-19 | M | A | 2,778 | $18.36 | 2,778 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. |
| 2 | Common | Common Stock | 2026-08-19 | S | D | 2,778 | $117.55 | 0 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. (F2) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.01 to $117.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-08-19 | M | D | 2,778 | $0.00 | 19,445 | D | $18.36 · — to 2035-05-22 | 2,778 Common Stock | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. (F3) The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |